CL2021002100A1 - Combinación farmacéutica que comprende tno155 y un inhibidor de pd–1. - Google Patents

Combinación farmacéutica que comprende tno155 y un inhibidor de pd–1.

Info

Publication number
CL2021002100A1
CL2021002100A1 CL2021002100A CL2021002100A CL2021002100A1 CL 2021002100 A1 CL2021002100 A1 CL 2021002100A1 CL 2021002100 A CL2021002100 A CL 2021002100A CL 2021002100 A CL2021002100 A CL 2021002100A CL 2021002100 A1 CL2021002100 A1 CL 2021002100A1
Authority
CL
Chile
Prior art keywords
inhibitor
tno155
pharmaceutical combination
treatment
compositions
Prior art date
Application number
CL2021002100A
Other languages
English (en)
Inventor
Ying-Nan Pan Chen
Huaixiang Hao
Chen Liu
Morvarid Mohseni
Silvia Goldoni
William D Hastings
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2021002100A1 publication Critical patent/CL2021002100A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una combinación farmacéutica que comprende TNO155 y un inhibidor de PD–1; composiciones farmacéuticas que la comprenden; y métodos de uso de dichas combinaciones y composiciones en el tratamiento o la prevención de afecciones en donde un inhibidor de SHP2 combinado con la inhibición de PD–1 es beneficioso en, por ejemplo, el tratamiento de cáncer.
CL2021002100A 2019-02-12 2021-08-10 Combinación farmacéutica que comprende tno155 y un inhibidor de pd–1. CL2021002100A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962804707P 2019-02-12 2019-02-12

Publications (1)

Publication Number Publication Date
CL2021002100A1 true CL2021002100A1 (es) 2022-04-18

Family

ID=69724012

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002100A CL2021002100A1 (es) 2019-02-12 2021-08-10 Combinación farmacéutica que comprende tno155 y un inhibidor de pd–1.

Country Status (13)

Country Link
US (1) US20220160706A1 (es)
EP (1) EP3923940A1 (es)
JP (1) JP2022519385A (es)
KR (1) KR20210126652A (es)
CN (1) CN113395967A (es)
AU (1) AU2020222295B2 (es)
BR (1) BR112021015487A2 (es)
CA (1) CA3129031A1 (es)
CL (1) CL2021002100A1 (es)
IL (1) IL284837A (es)
MX (1) MX2021009562A (es)
TW (1) TW202045172A (es)
WO (1) WO2020165733A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112867718A (zh) 2018-09-29 2021-05-28 诺华股份有限公司 用于抑制shp2活性的化合物和组合物的制造
WO2020072656A1 (en) 2018-10-03 2020-04-09 Gilead Sciences, Inc. Imidozopyrimidine derivatives
IL299131A (en) 2020-06-18 2023-02-01 Revolution Medicines Inc Methods for delaying, preventing and treating acquired resistance to RAS inhibitors
EP4208261A1 (en) 2020-09-03 2023-07-12 Revolution Medicines, Inc. Use of sos1 inhibitors to treat malignancies with shp2 mutations
EP4214209A1 (en) 2020-09-15 2023-07-26 Revolution Medicines, Inc. Indole derivatives as ras inhibitors in the treatment of cancer
MX2023007399A (es) * 2020-12-22 2023-07-06 Novartis Ag Combinaciones farmaceuticas que comprenden un inhibidor de kras g12c y usos de un inhibidor de kras g12c para el tratamiento de cancer.
WO2022133731A1 (en) * 2020-12-22 2022-06-30 Novartis Ag Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor and for the treatment of cancers
EP4334321A1 (en) 2021-05-05 2024-03-13 Revolution Medicines, Inc. Ras inhibitors
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
CN117616031A (zh) 2021-05-05 2024-02-27 锐新医药公司 用于治疗癌症的ras抑制剂
EP4334318A1 (en) * 2021-05-05 2024-03-13 Huyabio International, LLC Combination therapies comprising shp2 inhibitors and pd-1 inhibitors
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
TW202342040A (zh) 2022-02-21 2023-11-01 瑞士商諾華公司 藥物配製物
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL129299A0 (en) 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
CA2508660C (en) 2002-12-23 2013-08-20 Wyeth Antibodies against pd-1 and uses therefor
SI2439273T1 (sl) 2005-05-09 2019-05-31 Ono Pharmaceutical Co., Ltd. Človeška monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka z uporabo protiteles proti PD-1 samostojno ali v kombinaciji z ostalimi imunoterapevtiki
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
JP2012510429A (ja) 2008-08-25 2012-05-10 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよびその使用方法
WO2010029435A1 (en) 2008-09-12 2010-03-18 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
SI2342226T1 (sl) 2008-09-26 2016-11-30 Dana-Farber Cancer Institute Inc. Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
US8993731B2 (en) 2010-03-11 2015-03-31 Ucb Biopharma Sprl PD-1 antibody
DK2699264T3 (en) 2011-04-20 2018-06-25 Medimmune Llc ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
RU2604814C2 (ru) 2011-07-24 2016-12-10 Кьюртек Лтд. Варианты гуманизированных иммуномодулирующих моноклональных антител
SG11201508528TA (en) 2013-05-02 2015-11-27 Anaptysbio Inc Antibodies directed against programmed death-1 (pd-1)
US9676853B2 (en) 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
US20160145355A1 (en) 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
PL3702373T3 (pl) 2013-09-13 2022-12-05 Beigene Switzerland Gmbh Przeciwciała anty-PD1 i ich zastosowanie jako środki terapeutyczne i diagnostyczne
SG10201804945WA (en) 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2018130928A1 (en) * 2017-01-10 2018-07-19 Novartis Ag Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor

Also Published As

Publication number Publication date
JP2022519385A (ja) 2022-03-23
AU2020222295B2 (en) 2023-04-06
KR20210126652A (ko) 2021-10-20
US20220160706A1 (en) 2022-05-26
TW202045172A (zh) 2020-12-16
WO2020165733A1 (en) 2020-08-20
EP3923940A1 (en) 2021-12-22
IL284837A (en) 2021-08-31
AU2020222295A1 (en) 2021-08-05
CA3129031A1 (en) 2020-08-20
BR112021015487A2 (pt) 2021-10-05
CN113395967A (zh) 2021-09-14
MX2021009562A (es) 2021-09-08

Similar Documents

Publication Publication Date Title
CL2021002100A1 (es) Combinación farmacéutica que comprende tno155 y un inhibidor de pd–1.
CL2021002099A1 (es) Combinación farmacéutica que comprende tno155 y ribociclib.
EP4249000A3 (en) Pharmaceutical combination comprising tno155 and a krasg12c inhibitor
PH12021500004A1 (en) Pd-1/pd-l1 inhibitors
WO2019222112A8 (en) Mcl-1 inhibitors
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
EP4026835A3 (en) Pd-1/pd-l1 inhibitors
BR112021024108A2 (pt) Inibidores de tead e usos dos mesmos
CL2018002708A1 (es) Métodos para la inhibición de la angiogénesis en un sujeto que lo necesita
BR112021006392A2 (pt) moduladores da alfa-1 antitripsina
CO2019001212A2 (es) Composiciones y métodos de inhibición del masp-3 para el tratamiento de diversas enfermedades y trastornos
DOP2022000194A (es) Compuestos de tetralina y tetrahidroquinolina como inhibidores de hif-2alfa
AR119934A1 (es) Inhibidores de pikfyve para terapia contra el cáncer
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
BR112022001365A2 (pt) Formas cristalinas de um inibidor de cd73
ECSP20082339A (es) Moduladores de la expresión de apol1
EA202190776A1 (ru) Комбинация маломолекулярных ингибиторов cd-47 с другими противораковыми агентами
PE20210109A1 (es) Moduladores de la expresion de irf4
MX2022013867A (es) Combinacion farmaceutica que comprende tno155 y nazartinib.
CL2021000018A1 (es) Oligonucleótidos para modular la expresión de rtel1
BR112022005895A2 (pt) Inibidores de aldose redutase para tratamento de deficiência de fosfomanomutase 2
CL2020002505A1 (es) Una combinación farmacéutica triple que comprende dabrafenib, trametinib y un inhibidor de erk
CO2019007671A2 (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer
PE20201349A1 (es) Moduladores de la expresion de ezh2